-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Roche Pharma China announced on April 18 that it has reached a cooperation with Teva Pharmaceuticals (hereinafter referred to as "Teva") to expand the patient access of bendamustine orthohydrochloride-Cunda® in China.
Left: Mr.
Cunda® is the original research and development of bendamustine hydrochloride independently developed by Teva, which was approved in China in 2018 for the treatment of patients with disease progression during/after treatment with rituximab or rituximab-containing regimens.
Compared with the 5-year survival rate of about 70% in developed countries, the 5-year survival rate of Chinese lymphoma patients is still only 39%, which requires more innovative drugs and more standardized diagnosis and treatment
The cooperation between Roche and Teva will better leverage the synergistic effect of the original research + original research, and bring good survival benefits to the majority of Chinese lymphoma patients